On November 10th, the 24th Shanghai International Bio-Forum (BIO-FORUM) series, specifically the China Biotech & Pharmaceutical Innovation Forum, was grandly held in Shanghai, alongside the presentation of the 2022 China Biopharmaceutical Innovation Value Awards. During the selection process for the 2022 China Biopharmaceutical Industry Science and Technology Innovation Value Awards initiated by the conference, AceMab was honored as the "2022 Most Promising CXO Company".

The Innovation CXO Awards primarily focus on preclinical CROs, clinical CROs, CDMOs, CMOs, and related fields. Leading CXO enterprises, leveraging their first-mover advantages, have progressively established integrated platform layouts. Despite the recent fluctuations impacting biopharmaceutical innovation, these leaders have maintained rapid growth, forming the core group of the most influential CXO list. Emerging CXO players, whether excelling in specialized vertical segments or rapidly catching up as CDMO contenders, are demonstrating impressive growth momentum.

The "2022 China Biopharmaceutical Innovation Value Awards" was jointly launched by the Shanghai Association for Biopharmaceutical Industry and Mediscience. The judging committee, chaired by Huayi Research Institute, conducted a rigorous multi-stage evaluation, carefully assessing the comprehensive strength and development potential of hundreds of biopharmaceutical companies in the industry. Ultimately, AceMab was awarded the title of "Most Promising CXO Company".

Dr. Li Jianliang, CEO of AceMab, represented the company at the awards ceremony to accept the honor. Dr. Li expressed his sincere gratitude to the organizing committee and industry peers, receiving this well-deserved award.